Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): A systematic review and meta-analyses

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 336-345

  Turner, Dan ^a   Shah, Prakesh S ^b,c   Steinhart, A Hillary ^b,c   Zlotkin, Stanley ^c,d   Griffiths, Anne M ^c,d  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Crohn's disease; maintenance of remission; omega 3 fatty acids; ulcerative colitis

Indexed keywords

ARACHIDONIC ACID; MIGLYOL; OMEGA 3 FATTY ACID;

ARTICLE; BLOATING; CLINICAL TRIAL; CROHN DISEASE; DISGEUSIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; HALITOSIS; HEARTBURN; HOSPITAL READMISSION; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; RELAPSE; REMISSION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS; VOMITING;

CLINICAL TRIALS AS TOPIC; FATTY ACIDS, OMEGA-3; HUMANS; INFLAMMATORY BOWEL DISEASES; REMISSION INDUCTION; REVIEW LITERATURE AS TOPIC;

EID: 78650137504     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21374     Document Type: Article

References (75)

1. Turner D, Steinhart AH, Griffiths AM,. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007; CD006443.
2. Turner D, Zlotkin SH, Shah PS, et al. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009; CD006320.
3. Akabas SR, Deckelbaum RJ,. Summary of a workshop on n-3 fatty acids: current status of recommendations and future directions. Am J Clin Nutr. 2006; 83: 1536S-1538S.
4. Ergas D, Eilat E, Mendlovic S, et al. n-3 fatty acids and the immune system in autoimmunity. Isr Med Assoc J. 2002; 4: 34-38.
5. Hooper L, Thompson RL, Harrison RA, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease [Systematic Review]. Cochrane Database Syst Rev. 2004; CD003177.
6. Ruxton CH, Reed SC, Simpson MJ, et al. The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Diet. 2004; 17: 449-459.
7. Simopoulos AP,. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002; 21: 495-505.
8. Mayer K, Seeger W,. Fish oil in critical illness. Curr Opin Clin Nutr Metab Care. 2008; 11: 121-127.
9. Chapkin RS, Seo J, McMurray DN, et al. Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine. Chem Phys Lipids. 2008; 153: 14-23.
10. Kim YI,. Can fish oil maintain Crohn's disease in remission? Nutr Rev. 1996; 54: 248-252.
11. Lee TH, Hoover RL, Williams JD, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med. 1985; 312: 1217-1224.
12. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989; 320: 265-271.
13. Fisher M, Upchurch KS, Levine PH, et al. Effects of dietary fish oil supplementation on polymorphonuclear leukocyte inflammatory potential. Inflammation. 1986; 10: 387-392.
14. Lorenz R, Weber PC, Szimnau P, et al. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease-a randomized, placebo-controlled, double-blind cross-over trial. J Intern Med Suppl. 1989; 731: 225-232.
15. Belluzzi A, Brignola C, Campieri M, et al. Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients. Dig Dis Sci. 1994; 39: 2589-2594.
16. Vilaseca J, Salas A, Guarner F, et al. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut. 1990; 31: 539-544.
17. Nakazawa A, Hibi T,. Is fish oil (n-3 fatty acids) effective for the maintenance of remission in Crohn's disease? J Gastroenterol. 2000; 35: 173-175.
18. Belluzzi A,. N-3 fatty acids for the treatment of inflammatory bowel diseases. Proc Nutr Soc. 2002; 61: 391-395.
19. Endres S, Lorenz R, Loeschke K,. Lipid treatment of inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 1999; 2: 117-120.
20. MacLean CH, Mojica WA, Newberry SJ, et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr. 2005; 82: 611-619.
21. Turner D, Zlotkin SH, Shah PS, et al. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2007; CD006320.
22. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12.
23. Clark HD, Wells GA, Huet C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials. 1999; 20: 448-452.
24. Juni P, Altman DG, Egger M,. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001; 323: 42-46.
25. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560.
26. Trebble TM, Arden NK, Wootton SA, et al. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am J Clin Nutr. 2004; 80: 1137-1144.
27. Trebble TM, Stroud MA, Wootton SA, et al. High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial. Br J Nutr. 2005; 94: 253-261.
28. Nielsen AA, Jorgensen LGM, Nielsen JN, et al. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. Aliment Pharmacol Ther. 2005; 22: 1121-1128.
29. Eivindson M, Gronbaek H, Nielsen JN, et al. Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with omega-3 or omega-6 fatty acids and corticosteroids. Scand J Gastroenterol. 2005; 40: 1214-1221.
30. Seidman E, Bouthillier L, Thibault L, et al. Clinical and nutritional parameters in Crohn's disease patients treated with either an n-3 PUFA-enriched semi-elemtal or a polymeric diet. Results of a randimized controled trial. J Pediatr Gastroenterol Nutr. 2003; 37: 393.
31. Bamba T, Shimoyama T, Sasaki M, et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol. 2003; 15: 151-157.
32. Sakurai T, Matsui T, Yao T, et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas. JPEN J Parenter Enteral Nutr. 2002; 26: 98-103.
33. Socha P, Ryzko J, Koletzko B, et al. The influence of fish oil therapy in children with inflammatory bowel disease on the fatty acid status. Pediatr Wspolczesna. 2002; 4: 413-416.
34. Hillier K, Jewell R, Dorrell L, et al. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut. 1991; 32: 1151-1155.
35. Aslan A, Triadafilopoulos G,. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol. 1992; 87: 432-437.
36. Barbosa DS, Cecchini R, El Kadri MZ, et al. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition (Burbank). 2003; 19: 837-842.
37. Dichi I, Frenhane P, Dichi JB, et al. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. Nutrition (Burbank). 2000; 16: 87-90.
38. Stenson WF, Cort D, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med. 1992; 116: 609-614.
39. Seidner DL, Lashner BA, Brzezinski A, et al. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005; 3: 358-369.
40. Almallah YZ, Richardson S, O'Hanrahan T, et al. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol. 1998; 93: 804-809.
41. Tobin A, Suzuki Y, O'Morain C,. Controlled double blind cross over study of EPA in chronic ulcerative colitis [Abstract]. Gastroenterology. 1990; 98: A207.
42. Varghese TJ, Coomansingh D, Richardson S, et al. Clinical response of ulcerative colitis with dietary omega-3 fatty acids: a double-blind randomized study [Abstract #20]. Br J Surg. 2000; 87: 7.
43. Geerling BJ, Badart-Smook A, van Deursen C, et al. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis. 2000; 6: 77-84.
44. Bjorkkjaer T, Brunborg LA, Arslan G, et al. Reduced joint pain after short-term duodenal administration of seal oil in patients with inflammatory bowel disease: comparison with soy oil. Scand J Gastroenterol. 2004; 39: 1088-1094.
45. Almallah YZ, El-Tahir A, Heys SD, et al. Distal procto-colitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition. Eur J Clin Investig. 2000; 30: 58-65.
46. Almallah YZ, Ewen SW, El-Tahir A, et al. Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ. J Clin Immunol. 2000; 20: 68-76.
47. Greenfield SM, Green AT, Teare JP, et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther. 1993; 7: 159-166.
48. Middleton SJ, Naylor S, Woolner J, et al. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther. 2002; 16: 1131-1135.
49. Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA. 2008; 299: 1690-1697.
50. Belluzzi A, Campieri M, Belloli C, et al. A new enteric coated preparation of omega-3 fatty acids for preventing post-surgical recurrence in Crohn's disease. Gastroenterology. 1997; 112: A930.
51. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease [see Comment]. N Engl J Med. 1996; 334: 1557-1560.
52. Romano C, Cucchiara S, Barabino A, et al. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol. 2005; 11: 7118-7121.
53. Lorenz-Meyer H, Bauer P, Nicolay C, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol. 1996; 31: 778-785.
54. Hawthorne AB, Daneshmend TK, Hawkey a CJ, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut. 1992; 33: 922-928.
55. Loeschke K, Ueberschaer B, Pietsch A, et al. n-3 fatty acids only delay early relapse of ulcerative colitis in remission. Dig Dis Sci. 1996; 41: 2087-2094.
56. Mantzaris GJ, Archavlis E, Zografos C, et al. A prospective, randomized, placebo-controlled study of fish oil in ulcerative colitis. Hellenic J Gastroenterol. 1996; 9: 138-141.
57. McCall TB, O'Leary D, Bloomfield J, et al. Therapeutic potential of fish oil in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 1989; 3: 415-424.
58. Meister D, Ghosh S,. Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture: differential effects on ulcerative colitis and Crohn's disease. World J Gastroenterol. 2005; 11: 7466-7472.
59. Deckelbaum RJ, Worgall TS, Seo T,. n-3 fatty acids and gene expression. Am J Clin Nutr. 2006; 83: 1520S-1525S.
60. Bassaganya-Riera J, Hontecillas R,. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr. 2006; 25: 454-465.
61. Roy N, Barnett M, Knoch B, et al. Nutrigenomics applied to an animal model of Inflammatory Bowel Diseases: transcriptomic analysis of the effects of eicosapentaenoic acid- and arachidonic acid-enriched diets. Mutat Res. 2007; 622: 103-116.
62. Socha P, Ryzko J, Koletzko B, et al. Essential fatty acid depletion in children with inflammatory bowel disease. Scand J Gastroenterol. 2005; 40: 573-577.
63. Nieto N, Torres MI, Rios A, et al. Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. J Nutr. 2002; 132: 11-19.
64. Kuroki F, Iida M, Matsumoto T, et al. Serum n3 polyunsaturated fatty acids are depleted in Crohn's disease. Dig Dis Sci. 1997; 42: 1137-1141.
65. Siguel EN, Lerman RH,. Prevalence of essential fatty acid deficiency in patients with chronic gastrointestinal disorders. Metab Clin Exp. 1996; 45: 12-23.
66. Figler M, Gasztonyi B, Cseh J, et al. Association of n-3 and n-6 long-chain polyunsaturated fatty acids in plasma lipid classes with inflammatory bowel diseases. Br J Nutr. 2007; 97: 1154-1161.
67. el Boustani S, Colette C, Monnier L, et al. Enteral absorption in man of eicosapentaenoic acid in different chemical forms. Lipids. 1987; 22: 711-714.
68. Lawson LD, Hughes BG,. Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochem Biophys Res Commun. 1988; 152: 328-335.
69. Marquez Martin A, de la Puerta Vazquez R, Fernandez-Arche A, et al. Suppressive effect of maslinic acid from pomace olive oil on oxidative stress and cytokine production in stimulated murine macrophages. Free Radic Res. 2006; 40: 295-302.
70. Garud, Brown A, Cheiftez A, et al. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci. 2008; 53: 875-891.
71. Su C, Lewis JD, Goldberg B, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007; 132: 516-526.
72. Renna S, Orlando A, Mocciaro F, et al. Placebo therapy in Crohn's disease. Eur J Int Med. 2009; 20: 572-578.
73. Pascua, Su C, Lewis JD, et al. Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease. Aliment Pharmacol Ther. 2008; 28: 545-556.
74. Oh R,. Practical applications of fish oil (omega-3 fatty acids) in primary care. J Am Board Fam Pract. 2005; 18: 28-36.
75. Melanson SF, Lewandrowski EL, Flood JG, et al. Measurement of organochlorines in commercial over-the-counter fish oil preparations: implications for dietary and therapeutic recommendations for omega-3 fatty acids and a review of the literature. Arch Pathol Lab Med. 2005; 129: 74-77.